Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06304168 · ClinicalTrials.gov registry record

Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study

A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by Mayo Clinic.

Recruiting
Registry status
6,150
Enrollment target
1
Study location

NCT06304168 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 6,150 participants, above the 1,106-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (456% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06304168, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
6,150 participants
Enrollment target
1
Study location

Study Summary

This study explores the potential value of a new blood test approach for early detection of cancer.

Interventions

  • OTHER Non-Interventional Study

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 6,150 participants
Start Date 2019-05-13
Est. Completion 2028-05-15

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT06304168

The ClinicalTrials.gov registry entry for NCT06304168 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 6,150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,106-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (456% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.

NCT06304168 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT06304168 about?

NCT06304168 is a clinical study titled "Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study". This study explores the potential value of a new blood test approach for early detection of cancer.

What is the current status of trial NCT06304168?

This trial is currently recruiting. The enrollment target is 6,150 participants. The study started on 2019-05-13. Estimated completion is 2028-05-15.

What conditions does trial NCT06304168 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm.

What interventions are being tested in trial NCT06304168?

The interventions under investigation include: Non-Interventional Study (OTHER).

Who is sponsoring clinical trial NCT06304168?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06304168 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.